Funder
Taiho Oncology, Inc.
Taiho Pharmaceutical Co., Ltd.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference22 articles.
1. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545–549
2. Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W (2017) A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs 35(2):189–197
3. Bendell JC, Rosen LS, Mayer RJ et al (2015) Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 76(5):925–932
4. Doi T, Ohtsu A, Yoshino T et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429–434
5. Hong DS, Abbruzzese JL, Bogaard K et al (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383–1390